Today, Ambu is hosting a Capital Markets Day. In this context, Ambu will outline its assessment of market potential and dynamics as it expands on its ZOOM IN strategy. This includes innovative ...

Ambu raises its expectations for EBIT margin before special items to 5 - 6% (previously 3 - 5%) for the full-year 2022/23, based on its preliminary Q3 results. For Q3 2022/23, EBIT before special ...

In Q3 2025/26, Ambu delivered organic revenue growth of 10.3%, driven by strong performance in Endoscopy Solutions growing 16.0% organically.

Ambu's Board of Directors proposes the election of two new members – Susanne Larsson and Michael del Prado – at the annual general meeting in December 2021. Ambu A/S announces today that the Board of ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Good morning, everyone, and welcome to this Earnings Call this morning, where we will report on Ambu's First Quarter Results in our Fiscal Year 2023-2024. My name is Britt Meelby Jensen, and it's a ...

COLUMBIA, Md.--(BUSINESS WIRE)--The U.S. Food and Drug Administration has updated a safety communication on reprocessed flexible bronchoscopes. The FDA recommends that healthcare providers consider ...

Ambu A/S (ISIN DK0060946788) continues to build its strategy around single-use endoscopy, with the aScope 4 Broncho positioned as a flagship bronchoscopy solution in intensive care units. According to ...

COLUMBIA, Md.--(BUSINESS WIRE)--Ambu Inc., the world leader in single-use endoscopes, announced today that it has been awarded a single-use endoscopy contract in the category of Surgical Disposable ...

Today, Ambu announces its financial guidance for the fiscal year 2023/24. Also, today, Ambu will publish its Q4 and full-year earnings release along with its Annual Report, including the company’s ...